Clinical trials have reported sizable tumor regression (30%–63%) in 5 out of 25 patients with 10 different cancer diagnoses treated with TILs and low-dose IL-2 (200,000 IU/kg for 14 days), with no severe IL-2-related adverse effects reported (53). This evidence concerns the gene IL2 and neoplasm.